Zhou et al. found that CXCR4 may be a key player in tamoxifen resistance in breast cancer, as resistance is reversed when CXCR4 is knocked down or upon treatment with plerixafor due to inhibition of the AKT phosphorylation pathway [190]. The gene discussed is CXCR4; the disease is breast carcinoma.